# US 2023/0390340 A1 · Gene therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390340 A1
- Document ID: US20230390340A1
- Status: Published application
- Kind: A1
- Application number: 18/086,719
- Filed: 2022-12-22
- Published: 2023-12-07
- Earliest claimed: 2017-02-07
- Assignees: The University of Manchester
- Applicants: The University of Manchester
- Inventors: Brian Bigger; Hélène Gleitz
- Web page: https://patentgrep.com/patent/US20230390340A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/775: Apolipopeptides
- C12N 5/16: Animal cells
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 15/79: Vectors or expression systems specially adapted for eukaryotic hosts
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptides comprise iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acids comprise an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence. The invention also relates to haematopoietic stem and progenitor cells (HSPCs) transduced by such nucleic acids for use in therapies.

## Claims

### Claim 1

A nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence.

### Claim 2 (depends on 1)

The nucleic acid as claimed in claim 1, further comprising an intervening linker sequence located between the IDS sequence and the ApoEII sequence.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein the IDS sequence comprises a codon-optimised sequence of the wild-type IDS sequence.

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein the repeat of the ApoEII sequence is in the form of a tandem repeat.

### Claim 5 (depends on 1)

The nucleic acid of claim 1, wherein the IDS sequence comprises the sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 or a derivative sequence having at least 90% homology thereof, or the ApoEII sequence comprises one or more sequences according to SEO ID NO: 3 or a derivative sequence having at least 95% homology thereof.

### Claim 6

(canceled)

### Claim 7 (depends on 2)

The nucleic acid of claim 2, wherein the intervening linker sequence comprises the sequence according to SEQ ID NO: 4 or a derivative sequence having at least 95% homology thereof.

### Claim 8 (depends on 2)

The nucleic acid of claim 2, wherein the nucleic acid is incorporated in a gene therapy vector.

### Claim 9 (depends on 8)

The nucleic acid of claim 8, wherein the vector is a lentiviral vector.

### Claim 10 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid is transduced in one or more haematopoietic stem and progenitor cells (HSPCs).

### Claim 11 (depends on 1)

The nucleic acid of claim 1, for use in the treatment, management, retardation of progression or normalisation of development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency.

### Claim 12 (depends on 11)

The nucleic acid of claim 11, wherein the disease or condition comprises mucopolysaccharidosis type 11 (MPS 11) or Hunters syndrome.

### Claim 13

A composition comprising:
a) a first moiety comprising iduronate-2-sulfatase (IDS); and
b) a second moiety comprising a repeat of Apolipoprotein E (ApoE11).

### Claim 14 (depends on 13)

The composition of claim 13, wherein the repeat of Apolipoprotein ApoEII is in the form of a tandem repeat.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the first and second moiety have an intervening linker moiety located there between.

### Claim 16 (depends on 13)

The composition of claim 13, wherein the amino acid sequence of the first moiety comprises the sequence according to SEQ ID NO: 5 or a derivative sequence having at least 90% homology thereof, or the amino acid sequence of the second moiety comprise one or more sequences according to SEO ID NO: 7 or a derivative sequence having at least 95% homology thereof.

### Claim 17

(canceled)

### Claim 18 (depends on 15)

The composition of claim 15, wherein the amino acid sequence of the intervening linker moiety comprise the sequence according to SEQ ID NO: 8 or a derivative sequence having at least 95% homology thereof.

### Claim 19 (depends on 1)

The composition of claim 1, for use in the treatment, management, retardation of progression or normalisation of development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the disease or condition comprises mucopolysaccharidosis type II (MPS II) or Hunters syndrome.

### Claim 21 (depends on 1)

Haematopoietic stem and progenitor cells (HSPCs) for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the HSPCs have been removed from the patient, transduced ex vivo with the nucleic acid claimed in claim 1, and the transduced HSPCs administered to the individual.

### Claim 22

A method for delivering a deficient iduronate-2-sulfatase (IDS) protein into the brain across the blood brain barrier in an individual suffering from a condition resulting from the deficiency in the protein, the composition comprising a viral vector comprising the gene sequence coding for the deficient protein tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence, wherein the vector is transduced, ex vivo, with a population of haematopoietic stem and progenitor cells (HSPCs) and the transduced HSPCs administered to the individual where they express higher physiological levels of the deficient protein which are sufficient to cross the blood brain barrier.

### Claim 23 (depends on 22)

The method of claim 22, wherein vector comprises a sequence for a flexible linker between the gene sequence coding for the deficient protein and the tandem repeat of the Apolipoprotein E (ApoEII) gene sequence, or the ApoEII tandem repeat gene sequence comprises the sequence according to SEO ID NO: 3 or variant sequences having up to 95% homology thereof, or the flexible linker sequence comprises the sequence according to SEO ID NO: 4 or variant sequences having up to 95% homology thereof.

### Claim at position 24

-25. (canceled)

### Claim 26 (depends on 23)

The method of claim 23, wherein the HSPCs are autologous.

### Claim 27

A combination of a nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence and one or more haematopoietic stem and progenitor cells (HSPCs), wherein the nucleic acid is capable of transducing the HSPCs.
